For citations:
Mingalimov M.A., Baryak E.A., Misyurin A.V., Kesaeva L.A., Mkrtchyan A.S., Misyurina E.N., Donskoy M.A., Tolstykh T.N., Orlova M.S., Chudnova T.S., Ivanova D.D., Kochneva O.L., Zotina E.N., Makeshova A.B., Andreev S.S., Yatskov K.V., Samsonova I.V., Lysenko M.A. Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma. Oncohematology. 2025;20(3):22-26. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-3-22-26